KeynoteHematology

Explore an Investigational Immunotherapy Trial for Hematological Cancers

Our Keynote hematology clinical trials are studying pembrolizumab to see if it may help patients with hematological cancers. Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.

Pembrolizumab has been FDA-approved for use in certain types of cancer.

The Keynote clinical trials focus on the following hematological conditions:

  • Multiple Myeloma
  • Classical Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Primary Mediastinal and Diffuse Large B-cell Lymphoma
  • Richter Syndrome

If your patients have one of the conditions we are studying, you may want to consider a Keynote trial.

Clinical trials for various hematological cancers are underway. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.

7

Active Trials

2

Trials Recruiting

16

US Trial Locations